Business, energy, technology, markets and global industry news from Business News Today

androgen control

PharmaDeviceNews androgen control
Representative image: Pediatric endocrine care is drawing renewed attention as Neurocrine Biosciences’ CRENESSITY two-year CAHtalyst Pediatric data show durable hormone control, reduced glucocorticoid exposure and potential long-term clinical benefits for children with classic congenital adrenal hyperplasia.
Pharma & Biotech

Neurocrine’s CAHtalyst pediatric data sharpens the case for CRENESSITY durability

Steroid reduction is the real test in pediatric CAH. Neurocrine’s CRENESSITY data now faces the durability, access and adoption question.

Read More